{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:55Z","timestamp":1792783435216,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Conch Hospital","award":["F20190301"],"award-info":[{"award-number":["F20190301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s12325-020-01235-y","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T16:07:31Z","timestamp":1580486851000},"page":"1049-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-0703","authenticated-orcid":false,"given":"Lei","family":"Zha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer V.","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Tefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"issue":"7","key":"1235_CR1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2471\/BLT.15.158998","volume":"93","author":"C Arthur","year":"2015","unstructured":"Arthur C, Awa Marie CS, Bent HI, et al. Antimicrobial resistance: a priority for global health action. Bull World Health Organ. 2015;93(7):439.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"1235_CR2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2015.993381","volume":"16","author":"AK Thabit","year":"2015","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159\u201377.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1235_CR3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","volume":"54","author":"PD Mauldin","year":"2010","unstructured":"Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109\u201315.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"1235_CR4","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","volume":"362","author":"AY Peleg","year":"2010","unstructured":"Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med. 2010;362(19):1804\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"1235_CR5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","volume":"89","author":"P Hawkey","year":"2015","unstructured":"Hawkey P. Multidrug-resistant Gram-negative bacteria: a product of globalization. J Hosp Infect. 2015;89(4):241\u20137.","journal-title":"J Hosp Infect"},{"issue":"suppl_3","key":"1235_CR6","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","volume":"73","author":"PM Hawkey","year":"2018","unstructured":"Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018;73(suppl_3):iii2\u201378.","journal-title":"J Antimicrob Chemother"},{"key":"1235_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/841951","volume":"2014","author":"Branka Bedeni\u0107","year":"2014","unstructured":"Bedeni\u0107 B, Ple\u010dko V, Sardeli\u0107 S, Uzunovi\u0107 S, Godi\u010d Torkar K. Carbapenemases in Gram-negative bacteria: laboratory detection and clinical significance. BioMed Res Int. 2014;2014:841951.","journal-title":"BioMed Research International"},{"issue":"5","key":"1235_CR8","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1128\/AAC.02656-15","volume":"60","author":"R Tal-Jasper","year":"2016","unstructured":"Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2016;60(5):3127\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1235_CR9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785\u201396.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1235_CR10","first-page":"1","volume":"8","author":"DV Duin","year":"2017","unstructured":"Duin DV, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):1\u201310.","journal-title":"Virulence"},{"key":"1235_CR11","doi-asserted-by":"crossref","unstructured":"Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031\u201319.","DOI":"10.1128\/CMR.00031-19"},{"issue":"10","key":"1235_CR12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/phar.1636","volume":"35","author":"KS Kaye","year":"2015","unstructured":"Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35(10):949\u201362.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"1235_CR13","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/jac\/dkx322","volume":"72","author":"J Nowak","year":"2017","unstructured":"Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72(12):3277\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1235_CR14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/jac\/dkz030","volume":"74","author":"A P\u00e9rez","year":"2019","unstructured":"P\u00e9rez A, Gato E, P\u00e9rez-Llarena J, et al. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2019;74(5):1244\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"1235_CR15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fmicb.2014.00551","volume":"5","author":"N Cassir","year":"2014","unstructured":"Cassir N, Rolain J-M, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:551.","journal-title":"Front Microbiol"},{"issue":"5","key":"1235_CR16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/MCC.0b013e32827851d7","volume":"13","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care. 2007;13(5):592\u20137.","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"1235_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740338.2015.997206","volume":"14","author":"Q Kaewpoowat","year":"2015","unstructured":"Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015;14(2):335\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1235_CR18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","volume":"56","author":"DM Livermore","year":"2005","unstructured":"Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005;56(4):611\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1235_CR19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","volume":"56","author":"GA Pankey","year":"2005","unstructured":"Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470\u201380.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1235_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40121-019-0251-4","volume":"8","author":"JL Kuti","year":"2019","unstructured":"Kuti JL, Kim A, Cloutier DJ, Nicolau DP. Evaluation of plazomicin, tigecycline, and meropenem pharmacodynamic exposure against carbapenem-resistant Enterobacteriaceae in patients with bloodstream infection or hospital-acquired\/ventilator-associated pneumonia from the CARE Study (ACHN-490-007). Infect Dis Ther. 2019;8(3):383\u201396.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1235_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, Pan Y, Shen J, Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2017;16(1):24.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"6","key":"1235_CR22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000445425","volume":"61","author":"L Xu","year":"2016","unstructured":"Xu L, Wang Y-L, Du S, Chen L, Long L-H, Wu Y. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61(6):323\u201330.","journal-title":"Chemotherapy"},{"issue":"11","key":"1235_CR23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","volume":"11","author":"E Tasina","year":"2011","unstructured":"Tasina E, Haidich A-B, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834\u201344.","journal-title":"Lancet Infect Dis"},{"key":"1235_CR24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","volume":"39","author":"F Shen","year":"2015","unstructured":"Shen F, Han Q, Xie D, Fang M, Zeng H, Deng Y. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;39:25\u201333.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"1235_CR25","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699\u2013709.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1235_CR26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/17425255.2011.623126","volume":"7","author":"H Giamarellou","year":"2011","unstructured":"Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7(11):1459\u201370.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1235_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","volume":"44","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"1235_CR28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"Brian Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777.","journal-title":"Annals of Internal Medicine"},{"key":"1235_CR29","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011","unstructured":"Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011."},{"key":"1235_CR30","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"1235_CR31","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC,  al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7414","key":"1235_CR32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"TJP Higgins","year":"2003","unstructured":"Higgins TJP. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1235_CR33","first-page":"57","volume":"2","author":"K Thorlund","year":"2010","unstructured":"Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clin Epidemiol. 2010;2:57.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"1235_CR34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","volume":"46","author":"B Balandin Moreno","year":"2014","unstructured":"Balandin Moreno B, Fernandez Simon I, Pintado Garcia V, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis. 2014;46(3):175\u201380.","journal-title":"Scand J Infect Dis"},{"issue":"38","key":"1235_CR35","doi-asserted-by":"crossref","first-page":"e12467","DOI":"10.1097\/MD.0000000000012467","volume":"97","author":"Z Chen","year":"2018","unstructured":"Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine. 2018;97(38):e12467.","journal-title":"Medicine"},{"key":"1235_CR36","doi-asserted-by":"crossref","unstructured":"De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.","DOI":"10.1186\/cc13858"},{"issue":"8","key":"1235_CR37","doi-asserted-by":"crossref","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","volume":"97","author":"Ting-Ting Geng","year":"2018","unstructured":"Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine (Baltimore). 2018;97(8):e9961.","journal-title":"Medicine"},{"key":"1235_CR38","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.2147\/DDDT.S181834","volume":"12","author":"MM Ibrahim","year":"2018","unstructured":"Ibrahim MM, Abuelmatty AM, Mohamed GH, et al. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights. Drug Des Dev Ther. 2018;12:4171\u20139.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"1235_CR39","first-page":"47","volume":"28","author":"E Maseda","year":"2015","unstructured":"Maseda E, Su\u00e1rez-de-la-Rica A, Anillo V, et al. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients. Rev Esp Quimioter. 2015;28(1):47\u201353.","journal-title":"Rev Esp Quimioter"},{"issue":"10","key":"1235_CR40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/23744235.2015.1049659","volume":"47","author":"KZ Vardakas","year":"2015","unstructured":"Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. Infect Dis. 2015;47(10):751\u20133.","journal-title":"Infect Dis"},{"key":"1235_CR41","first-page":"1","volume":"2016","author":"Xiaomai Wu","year":"2016","unstructured":"Wu X, Zhu Y, Chen Q, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant Gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. BioMed Res Int. 2016;2016:8395268.","journal-title":"BioMed Research International"},{"key":"1235_CR42","doi-asserted-by":"crossref","unstructured":"Di Carlo P, Gulotta G, Casuccio A, et al. KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol. 2013;13(1):13.","DOI":"10.1186\/1471-2253-13-13"},{"issue":"4","key":"1235_CR43","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","volume":"57","author":"J Ramirez","year":"2013","unstructured":"Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756\u201362.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1235_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000118660","volume":"54","author":"DC Draghi","year":"2008","unstructured":"Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy. 2008;54(2):91\u2013100.","journal-title":"Chemotherapy"},{"issue":"2","key":"1235_CR45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jiac.2014.10.009","volume":"21","author":"C Rizek","year":"2015","unstructured":"Rizek C, Ferraz JR, van der Heijden IM, et al. In vitro activity of potential old and new drugs against multidrug-resistant Gram-negatives. J Infect Chemother. 2015;21(2):114\u20137.","journal-title":"J Infect Chemother"},{"issue":"9","key":"1235_CR46","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","volume":"66","author":"D Yahav","year":"2011","unstructured":"Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963\u201371.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1235_CR47","doi-asserted-by":"crossref","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","volume":"95","author":"Wentao Ni","year":"2016","unstructured":"Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(11):e3126.","journal-title":"Medicine"},{"issue":"6","key":"1235_CR48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jinf.2014.11.003","volume":"70","author":"KZ Vardakas","year":"2015","unstructured":"Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. 2015;70(6):592\u20139.","journal-title":"J Infect"},{"issue":"1","key":"1235_CR49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13756-018-0404-3","volume":"7","author":"S Siwakoti","year":"2018","unstructured":"Siwakoti S, Subedi A, Sharma A, Baral R, Bhattarai NR, Khanal B. Incidence and outcomes of multidrug-resistant Gram-negative bacteria infections in intensive care unit from Nepal-a prospective cohort study. Antimicrob Resist Infect Control. 2018;7(1):114.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1235_CR50","doi-asserted-by":"crossref","first-page":"11715","DOI":"10.1038\/srep11715","volume":"5","author":"Q Liu","year":"2015","unstructured":"Liu Q, Li X, Li W, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep. 2015;5:11715.","journal-title":"Sci Rep"},{"issue":"9","key":"1235_CR51","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00750-12","volume":"56","author":"L Morata","year":"2012","unstructured":"Morata L, Cobos-Trigueros N, Mart\u00ednez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012;56(9):4833\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1235_CR52","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1093\/jac\/dkz337","volume":"74","author":"H Mei","year":"2019","unstructured":"Mei H, Yang T, Wang J, Wang R, Cai Y. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(12):3423\u201331.","journal-title":"J Antimicrob Chemother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01235-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:15:47Z","timestamp":1744701347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01235-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01235-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"8 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}